BUFFALO BIOLABS, LLC

Address

73 HIGH ST
BUFFALO, NY, 14203-0000

http://www.buffalobiolabs.com

Information

DUNS: 830459546
# of Employees: 31

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine

    Amount: $288,029.00

    PROJECT SUMMARY ABSTRACT Antiviral vaccines remain the largest segment of the rapidly growing global vaccine market Despite near complete eradication of poliovirus through vaccination efforts contin ...

    SBIRPhase I2016Department of Health and Human Services
  2. Deimmunized TLR5 Agonist for Anticancer Therapy

    Amount: $223,303.00

    ABSTRACT: Radiotherapy is widely used to treat various types of cancer; however, its effectiveness is frequently limited by severe adverse effects resulting from radiation-induced damage to normal tis ...

    SBIRPhase I2014Department of Health and Human Services
  3. Testing of novel anti-cancer compounds Curaxins against pancreatic cancer

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Mortality from pancreatic ductal adenocarcinoma (PDA) is close to 100% due to the absence of effective treatment approaches. This proposal is focused on determini ...

    STTRPhase I2012Department of Health and Human Services
  4. Suv39H Targeted Therapy for Treatment of Childhood Rhabdomyosarcoma

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Rhabdomyosarcoma (RMS) is a childhood malignant tumor and is thought to arise due to the arrest of skeletal muscle differentiation (myogenesis) program. It account ...

    STTRPhase I2012Department of Health and Human Services
  5. IGF::OT::IGF OTHER FUNCTIONS RandD- MEDICAL BIOMEDICAL (BASIC RESEARCH)

    Amount: $200,000.00

    Head and neck (HandN) cancer is recognized as a significant threat to public health and a substantial economic challenge. The efficacy of radiotherapy widely used to treat HandN cancer is limited by s ...

    SBIRPhase I2012Department of Health and Human Services
  6. TAS::75 0849::TAS SBIR TOPIC 255 PHASE II DEVELOPMENT OF ANTICANCER AGENTS

    Amount: $1,496,764.00

    Aberrant functioning of proteins within stress response pathways (e.g. p53, NF-B, heat shock response) are prominent features in many cancer types. Such alterations have been associated with poor resp ...

    SBIRPhase II2011Department of Health and Human Services
  7. Targeting MLL As Anticancer Therapy for Infant Acute Lymphoblastic Leukemia

    Amount: $130,694.00

    DESCRIPTION (provided by applicant): Advances in treatment strategies have increased the long-term survival of children with acute lymphoblastic leukemia (ALL). However, the outlook of infants with AL ...

    SBIRPhase I2009Department of Health and Human Services
  8. Safety/Efficacy of Liposomal Reversan, a novel MRP1 modulator for Cancer Therapy

    Amount: $104,608.00

    DESCRIPTION (provided by applicant): One of the major problems in the fight against cancer is the intrinsic or acquired resistance of tumors to current cancer treatments, particularly that associated ...

    STTRPhase I2009Department of Health and Human Services
  9. Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 5

    Amount: $109,719.00

    DESCRIPTION (provided by applicant): Systemic treatment with the bacterial flagellin protein, a Toll-like receptor 5 (TLR5) agonist, provides protection against high dose radiation through activation ...

    SBIRPhase I2009Department of Health and Human Services
  10. #258 PREVENTING ADVERSE EFFECTS OF RADIOTHERAPY WITH CBLB502

    Amount: $149,987.00

    SBIRPhase IDepartment of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government